BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 13, 2026
See today's BioWorld
Home
» Six drugs to watch in China for 2026
To read the full story,
subscribe
or
sign in
.
Six drugs to watch in China for 2026
Jan. 16, 2026
By
Tamra Sami
No Comments
As China emerges as a critical commercial market and a source of global innovation, the newly released 2026 edition of Clarivate’s
Drugs to Watch
report highlights six drugs to watch in the China market for the year ahead.
BioWorld
Analysis and data insight
Cancer
Endocrine/metabolic
Immune
Asia-Pacific
China
NMPA